AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01114672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50,000 Units Ergocalciferol
Description: 50,000 Units oral ergocalciferol to be given once weekly
Study NCT01114672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo once weekly
Study NCT02452099 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryopreservation of HSCs using 5% DMSO concentration
Description: Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.
Study NCT02452099 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryopreservation of HSCs using 7,5% DMSO concentration
Description: Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.
Study NCT02452099 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryopreservation of HSCs using 10% DMSO concentration
Description: Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
Study NCT01537185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 cohorts of normal saline injection
Study NCT01537185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPWCV+Alum 100 mcg
Description: 3 injections 28 days apart
Study NCT01537185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPWCV+Alum 600 mcg
Description: 3 injections 28 days apart
Study NCT01537185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPWCV+Alum 300 mcg
Description: 3 injections 28 days apart
Study NCT00784745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2mg morning and night for 5 days.
Study NCT04014790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGI-2001
Description: Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
Study NCT04014790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care prophylaxis regimen will be administered according to institutional guidelines
Study NCT02460562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S-PRG filler
Description: Surface pre-reacted glass-ionomer (S-PRG) filler is a new type of biological material. This new material is being used in the formulation of dental product as filling materials. It has an anti-plaque effect which will release ions to alter the pH of the surrounding environment when it comes into contact with water or acidic solutions. These ions will exert their effect on caries prevention.~The amount of S-PRG filler that is put in the standard resin denture base is 20% by weight. They are incorporated into the resin denture base and maintain the mechanical properties as required by ISO 1567.
Study NCT02460562 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMMA resin
Description: Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
Study NCT02460562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA resin
Description: Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
Study NCT03102866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT03102866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo aerobic and strength training exercise
Study NCT03102866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03102866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03102866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03102866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02323737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan and cisplatin
Study NCT02323737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide and cisplatin
Study NCT02620358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T Tube for 120 minuts
Description: Spontaneous Breathing Trial using T Tube for 120 minutes.
Study NCT02620358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation of 8 cmH2O for 30 minutes
Description: Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
Study NCT04103515 — intervention group
Intervention type: DEVICE
Intervention: Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
Description: Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
Study NCT04103515 — intervention group
Intervention type: DEVICE
Intervention: Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
Description: Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
Study NCT00617513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 0.5 mg once daily
Study NCT00617513 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.
Study NCT03818243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diary (for reporting all impulse control disorders especially compulsive eating disorders)
Description: During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.
Study NCT00617513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 1 mg o.d.
Study NCT00617513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg o.d.
Study NCT02427802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin collagen sponge
Description: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
Study NCT02427802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching collagen sponge
Study NCT01081405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOTAL LYMPHOID IRRADIATION
Description: Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
Study NCT04622072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5809-TT1 Tablet
Description: Single tartrate of XZP-5809
Study NCT02254057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBT 986 BS - single rising dose
Study NCT02254057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02249013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery (CRS)
Description: CRS was performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity.
Study NCT02249013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Description: HIPEC was performed according to the closed-abdomen technique using CDDP (25 mg/L of perfusate/m2, total limit of 240mg) for the first 10 patients and thus, using CDDP plus Doxorubicin (15mg/L) thereafter, both for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 4L to 6L) was circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min.
Study NCT02249013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NACT)
Description: Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
Study NCT02249013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
Study NCT02249013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast-track recovery strategy
Description: A comprehensive fast-track program was applied to accelerate recovery, reduce morbidity, and shorten convalescence for patients enrolled in our trial.
Study NCT01048086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic Acid
Description: 160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children \<12 kg.
Study NCT01048086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in the same manner as retinoic acid in capsules that look identical.
Study NCT04559425 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
Study NCT04559425 — intervention group
Intervention type: OTHER
Intervention: No Dexamethasone
Description: All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
Study NCT05535322 — intervention group
Intervention type: DRUG
Intervention: GLP-1RA
Description: All T2D adults treated with Glucagon-like peptide-1 receptor agonists (GLP-1RA) or initiating a GLP-1RA during the study period
Study NCT05535322 — intervention group
Intervention type: DRUG
Intervention: SGLT2i
Description: SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
Study NCT05535322 — intervention group
Intervention type: DRUG
Intervention: Insulin
Description: Insulin users with no GLP-1RA and/or SGLT2i prescriptions: all T2D adults treated with insulin or initiating insulin treatment during the study period and who were not treated with GLP-1RA/SGLT2i
Study NCT05535322 — intervention group
Intervention type: DRUG
Intervention: Miscellany
Description: Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period and who were treated with other glucose-lowering agents during the study period
Study NCT04166292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stylage® XL Lidocaïne
Description: On V1 (D0), a total volume of 8 mL maximum can be used per subject on the whole face.~On V2 (M1), a possible touch-up can be made according to the injector and subject's opinion which cannot exceed 4 ml.
Study NCT02215499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02215499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02215499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02215499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Oxybate
Study NCT02215499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP-386
Study NCT02265757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual.
Study NCT02265757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Brain Fitness Training
Description: Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program and will be encouraged to maintain 250 minutes of computerized brain training per week for 18 months post program. Each participant's adherence and progress will be tracked through the clinician portal provided by Posit Science both during HABIT and for 18 months post-program.
Study NCT03922607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-157
Description: ABBV-157 will be administered orally as capsule
Study NCT02265757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group (patient and partner)
Description: Patient: The patient support group will meet for 45-60 minutes daily. It will use the LifeBio Memory Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
Study NCT03922607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-157
Description: Placebo for ABBV-157 will be administered orally as capsule
Study NCT01388062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosensing antibody probing system (e- Ab sensor)
Description: Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
Study NCT01189422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teplizumab or placebo
Description: infusion or injection
Study NCT04216485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: Dietary intervention combined with healthy lifestyle counseling
Study NCT04216485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard prenatal care on diet, nutrition and physical activity
Study NCT01486368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03446962
Description: PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.
Study NCT01187745 — intervention group
Intervention type: OTHER
Intervention: CT Scan followed by ultrasound
Description: A limited U/S is performed after the CT scan which is ordered by the Emergency Department physician.
Study NCT05294718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal shunt
Description: glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
Study NCT05294718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External shunt
Description: Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
Study NCT04699097 — intervention group
Intervention type: DRUG
Intervention: Azithromycin
Description: 250 mg tablet, 5 ml / 200 mg 30 ml suspension
Study NCT02265757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Education
Description: The education component will involve daily 60-minute group sessions with topics including Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition and Exercise, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
Study NCT02265757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The HABIT physical exercise intervention is intended to initiate and sustain a schedule rather than a type of physical activity. HABIT will provide a customized DVD as a supplement for continued use and practice after the program to those that opt to continue yoga. Will use an activity log completed by the partner to track activity level of the participants during the 18 month follow-up period.
Study NCT02544958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
Study NCT00951106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulfdoxine (Fansidar)
Study NCT01728207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU-114
Description: hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
Study NCT02338427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Study NCT02338427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proteomic analysis
Study NCT03028259 — intervention group
Intervention type: OTHER
Intervention: lab results
Description: Comparison of lab results
Study NCT02673294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance virtual rehabilitation
Study NCT01560572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus OD, mycophenolic acid, prednisolone
Description: tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
Study NCT01560572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus OD, mycophenolic acid, prednisolone
Description: tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
Study NCT04525131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM
Description: CPX-POM
Study NCT02795936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Perform exercise prescription for 12 weeks
Study NCT02795936 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Perform exercise prescription for 12 weeks
Study NCT03295175 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hematoxylin-eosin and smooth muscle actin markers
Description: The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:~1. Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.~2. Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present.
Study NCT01665482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A 2000 kcal test meal
Study NCT01665482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate
Study NCT04324515 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic gastric bypass with or without cholecystectomy
Description: Study Arm: robotic gastric bypass without cholecystectomy Control Arm: robotic gastric bypass with cholecystectomy
Study NCT02739451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard oxygen
Description: Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either~* low-flow oxygen \[including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask\]~* or medium-flow oxygen \[Venturi masks and medium-flow facemasks\]